Early detection and management of pulmonary arterial hypertension

European Respiratory Review

Volumn 21, Issue 126, 2012, Pages 306-312

  Humbert, Marc ^a   Coghlan, J Gerry ^b   Khanna, Dinesh ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Early intervention; Pulmonary arterial hypertension; Screening

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CARBON MONOXIDE; FENFLURAMINE; PLACEBO; PROSTANOID; SILDENAFIL; TADALAFIL;

BMPR2 GENE; CLINICAL TRIAL (TOPIC); CONGENITAL HEART DISEASE; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; ECHOCARDIOGRAPHY; EXERCISE; FALSE NEGATIVE RESULT; FAMILY HISTORY; GENE; GENE MUTATION; HEART CATHETERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DIFFUSION CAPACITY; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG VASCULAR RESISTANCE; MEDICAL EXPERT; OPEN STUDY; OVERALL SURVIVAL; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SICKLE CELL ANEMIA; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; WALKING;

ANEMIA, SICKLE CELL; ANTIHYPERTENSIVE AGENTS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PURINES; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SULFONAMIDES; SULFONES; VASODILATOR AGENTS;

EID: 84870762683     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005112     Document Type: Review

References (26)

1. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-1087.
3. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
4. Humbert M, Sitbon O, Yai{dotless}̈ci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
5. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
6. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.
7. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
8. Galie' N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
9. Gibbs JSR. Making a diagnosis in PAH. Eur Respir Rev 2007; 16: 8-12.
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
11. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
12. Black WC, Welch HG. Screening for disease. AJR Am J Roentgenol 1997; 168: 3-11.
13. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800.
14. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society, and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
15. Meune C, Avouac J, Airo' P, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63: 2790-2796.
16. Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum 2011; 63: 3531-3539.
17. Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-1839.
18. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365: 44-53.
19. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-466.
20. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-291.
21. McLaughlin VV, Coghlan JG, Denton CP, et al. An evidence-based screening algorithm for pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Chest 2012. Atlanta, USA.
22. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011; 140: 1274-1283.
23. Galie' N, Brundage B, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2008; 119: 2894-2903.
24. Galie' N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
25. Simonneau G, Galie' N, Hoeper MM, et al. An interim analysis of long-term outcome in patients treated with bosentan in the double-blind or open-label extension of the EARLY trial. Am J Respir Crit Care Med 2011; 183: A5886.
26. Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49: 490-500.